Edesa Biotech, Inc. SEC filings EDSA
Edesa Biotech, Inc. has 751 filings in SEC EDGAR's recent list, going back to Feb 3, 2012. Its latest annual report, Form ARS, was filed on Apr 3, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (officer or director change). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Aug 20, 2026 | — |
| 424B5 | Prospectus supplement | Aug 19, 2026 | — |
| 424B3 | Prospectus | Jul 13, 2026 | — |
| S-3 | Shelf registration | Jul 2, 2026 | — |
| S-8 | Employee stock plan registration | May 29, 2026 | — |
| 424B5 | Prospectus supplement | Dec 12, 2025 | — |
| 424B5 | Prospectus supplement | Sep 9, 2025 | — |
| S-3 | Shelf registration | Jul 25, 2025 | — |
| S-8 | Employee stock plan registration | May 28, 2025 | — |
| 424B3 | Prospectus | Mar 11, 2025 | — |
| S-3 | Shelf registration | Mar 4, 2025 | — |
| 424B5 | Prospectus supplement | Oct 4, 2024 | — |
| S-8 | Employee stock plan registration | May 31, 2024 | — |
| S-8 | Employee stock plan registration | May 24, 2023 | — |
| 424B5 | Prospectus supplement | Mar 27, 2023 | — |
| 424B3 | Prospectus | Dec 23, 2022 | — |
| S-3 | Shelf registration | Dec 16, 2022 | — |
| S-3 | Shelf registration | Aug 5, 2022 | — |
| 424B4 | Prospectus | Apr 19, 2022 | — |
| S-1 | Registration statement | Apr 11, 2022 | — |
| 424B5 | Prospectus supplement | Mar 23, 2022 | — |
| 424B5 | Prospectus supplement | Mar 4, 2022 | — |
| 424B5 | Prospectus supplement | Dec 28, 2021 | — |
| 424B5 | Prospectus supplement | Nov 22, 2021 | — |
| S-8 | Employee stock plan registration | Apr 23, 2021 | — |
| 424B5 | Prospectus supplement | Feb 26, 2021 | — |
| FWP | Free writing prospectus | Feb 26, 2021 | — |
| 424B5 | Prospectus supplement | Feb 26, 2021 | — |
| FWP | Free writing prospectus | Feb 25, 2021 | — |
| 424B5 | Prospectus supplement | Feb 25, 2021 | — |
| 424B5 | Prospectus supplement | Sep 28, 2020 | — |
| S-1 | Registration statement | Feb 25, 2020 | — |
| S-8 | Employee stock plan registration | Jan 28, 2020 | — |
| 424B5 | Prospectus supplement | Jan 6, 2020 | — |
| S-3 | Shelf registration | Aug 30, 2019 | — |
| POS AM | Filing | Dec 5, 2018 | — |
| POS AM | Filing | Dec 4, 2018 | — |
| 424B3 | Prospectus | Oct 2, 2018 | — |
| 424B3 | Prospectus | Aug 8, 2018 | — |
| 424B4 | Prospectus | Jun 18, 2018 | — |
| S-1 | Registration statement | Jun 6, 2018 | — |
| 424B4 | Prospectus | May 14, 2018 | — |
| S-1/A | Amended registration statement | May 8, 2018 | — |
| S-1 | Registration statement | Apr 17, 2018 | — |
| S-8 | Employee stock plan registration | Apr 26, 2017 | — |
| 424B3 | Prospectus | Sep 29, 2016 | — |
| S-3 | Shelf registration | Sep 16, 2016 | — |
| 424B5 | Prospectus supplement | Jun 30, 2016 | — |
| S-3 | Shelf registration | Apr 23, 2015 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EDSA (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1540159
- Former names
- Stellar Biotechnologies, Inc. (until May 30, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.